安旭生物(688075.SH):以1709萬元競得杭州市數字商貿城一地塊使用權
格隆匯4月11日丨安旭生物(688075.SH)公佈,公司於近日按照法定程序參與了杭州市數字商貿城單元JG1801-M1-14地塊(地塊編號:杭政工出【2023】2號)土地使用權的掛牌出讓競拍,最終以1709.00萬元競得上述地塊12,547平方米(最終面積以土地登記證面積為準)的國有建設用地使用權,公司已收到杭州市規劃和自然資源局出具的《成交確認書》。
本次競拍的土地公司擬用於建設要素齊全、環節完備的生物醫藥高端產業研發製造及管理中心,用於公司在生物原料、免疫層析、乾式生化、化學發光、精準檢測五大技術平台的研發、前沿技術研究佈局以及醫療儀器設備產品的生產製造等。項目建成後,公司將不斷深耕IVD領域,開發更多的產品和服務,有利於公司吸引研發、銷售和管理等高端人才,助力公司高質量發展,符合公司未來戰略發展規劃,對公司的持續經營能力將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.